Benzinga | Sep 8, 2020 06:19AM EDT

Citigroup Initiates Coverage On Eidos Therapeutics with Buy Rating, Announces Price Target of $80

Citigroup analyst Joel Beatty initiates coverage on Eidos Therapeutics (NASDAQ:EIDX) with a Buy rating and announces Price Target of $80.